Abbott Laboratories, a major healthcare company, has agreed to pay $385 million to resolve claims related to an investigation and lawsuit brought by the U.S. Department of Justice. The case involves Abbott’s manufacturing practices and a 2022 recall of its powdered infant formula produced at a facility in Sturgis, Michigan. The settlement, which Abbott says does not admit any fault or liability, also addresses lawsuits from state attorneys general and certain relators—individuals who assist in legal cases in exchange for a share of the recovery. The plant, described as the largest baby formula production site in the United States, was shut down in February 2022 after the Food and Drug Administration (FDA) began an investigation into possible safety issues. It was later reopened in June of the same year after the recall. The 2022 recall involved several of Abbott’s infant formula brands, including Similac, and worsened an already tight supply chain situation. This shortage had been exacerbated by the ongoing effects of the COVID-19 pandemic, which had disrupted global supply chains and led to increased stockpiling of goods. Abbott stated that tests conducted by government regulators on unopened formula from the homes of infants under investigation at the time of the recall found no presence of Cronobacter sakazakii, a rare but serious bacterium that can cause severe illness in infants. The company also emphasized that no unopened, distributed Abbott infant formula has ever tested positive for this bacteria. The criminal investigation into the matter was closed during the Trump administration, though no charges were filed. In response to the supply shortage, the Biden administration took several steps to stabilize the market. These included relaxing import rules for foreign manufacturers, airlifting formula from Europe, and using federal emergency powers to prioritize U.S. production. The situation highlighted the importance of maintaining a stable supply of essential goods during crises and the complex interplay between government regulation, corporate responsibility, and public health.